Viewing Study NCT03167957


Ignite Creation Date: 2025-12-24 @ 6:51 PM
Ignite Modification Date: 2026-01-01 @ 4:20 PM
Study NCT ID: NCT03167957
Status: WITHDRAWN
Last Update Posted: 2019-03-08
First Post: 2017-05-23
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Efficacy and Safety of Oral Encochleated Amphotericin B (CAMB) in the Treatment of Fluconazole-Resistant Vulvovaginal Candidiasis
Sponsor: Matinas BioPharma Nanotechnologies, Inc.
Organization:

Study Overview

Official Title: A Single-Center, Open-Label, Pilot Study to Evaluate the Efficacy and Safety of Oral Encochleated Amphotericin B (CAMB) in the Treatment of Fluconazole-Resistant Vulvovaginal Candidiasis
Status: WITHDRAWN
Status Verified Date: 2019-03
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: No longer target indication
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: This is a single-center, open-label, pilot study to evaluate the efficacy of 14 days of CAMB dosing in subjects with fluconazole-resistant vulvovaginal candidiasis (VVC).
Detailed Description: This is a single-center, open-label, pilot study to evaluate the efficacy of 14 days of CAMB dosing in subjects with fluconazole-resistant vulvovaginal candidiasis (VVC).

Approximately 16 women with fluconazole-resistant VVC will be randomized to either 200 mg or 400 mg oral CAMB for 14 days. The primary objectives of this study are to assess the clinical cure rate, mycology eradication and responder outcome. The secondary objective of this study is to evaluate the safety of 200 mg and 400 mg doses of oral CAMB.

Study Oversight

Has Oversight DMC: False
Is a FDA Regulated Drug?: True
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: